CASTRATION-RESISTANT PROSTATE CANCER

This early-stage study tests a new drug called IDE034 in about 150 adults with advanced solid tumors (like lung, ovarian, or colon cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink …

This study tests whether combining two drugs, cabozantinib and nivolumab, can slow the growth of prostate cancer that has spread and stopped responding to hormone therapy. About 47 men will receive the treatment. The main goal is to see how long the cancer stays under control.

This early-stage trial tests an experimental drug called GZ17-6.02 in 30 men with castration-resistant prostate cancer that has worsened despite hormone therapy. The main goal is to see if the drug can delay cancer growth for at least 6 months. Researchers will also measure chang…

This early-stage study tests a new drug, JANX014, in 43 men with a hard-to-treat type of prostate cancer that has spread and stopped responding to standard hormone therapy and chemotherapy. The main goals are to check the drug's safety and find the right dose, while also looking …

This study looks at whether giving radiation alone or with hormone therapy works better for men whose prostate cancer has returned and spread. It also tests if adding pelvic radiation helps stop further spread. About 532 men with recurrent, hormone-sensitive prostate cancer will …

This study is for men with a specific type of advanced prostate cancer that has stopped responding to standard hormone therapy. The treatment combines high-dose testosterone with a chemotherapy drug called carboplatin. The goal is to see if this approach can lower PSA levels and …

This early-stage study tests a new oral drug, DCC-2812, in about 60 people with advanced kidney, bladder, or prostate cancer that has spread or not responded to other treatments. The main goals are to check safety and find the right dose, while also watching for any tumor shrinka…

This study tests whether adding a drug called carotuximab to the standard treatment apalutamide can help men with a type of advanced prostate cancer that has stopped responding to previous therapies. About 100 participants will be enrolled to see if the combination delays cancer …

This study tests a new radioactive drug (161Tb-RAD402) designed to find and attack prostate cancer cells that no longer respond to standard hormone therapy. About 73 men with castration-resistant prostate cancer will receive the drug to see if it is safe and can shrink tumors or …

This study looks at how hormone therapy changes PSMA levels in men with prostate cancer. Researchers want to find the best time to do a PSMA PET scan after starting treatment. About 80 men with either castration-sensitive or castration-resistant prostate cancer will take part. Th…

This study looks at whether markers in the blood can tell doctors if a man's advanced prostate cancer will respond to hormone therapy. Researchers will collect blood samples from 120 men with metastatic castration-resistant prostate cancer during their standard treatment. They wi…